- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
South San Francisco Today
By the People, for the People
Mangrove Partners IM LLC Increases Stake in CG Oncology
Institutional investor boosts holding in clinical-stage biotech company
Mar. 14, 2026 at 10:56am
Got story updates? Submit your updates here. ›
Mangrove Partners IM LLC, an institutional investor, increased its stake in CG Oncology, Inc. (NASDAQ:CGON) by 21% during the third quarter. The firm now owns 671,692 shares, or 0.88% of the clinical-stage biopharmaceutical company focused on antibody-based cancer immunotherapies.
Why it matters
CG Oncology's stock has seen significant gains over the past year as the company advances its pipeline of novel cancer treatments. Mangrove Partners' increased investment signals confidence in the company's prospects and potential for future growth.
The details
According to a regulatory filing, Mangrove Partners IM LLC purchased an additional 116,575 shares of CG Oncology during the third quarter, bringing its total holding to 671,692 shares. This represents approximately 2.3% of Mangrove's total investment portfolio.
- Mangrove Partners IM LLC increased its CG Oncology stake during the third quarter of 2025.
The players
Mangrove Partners IM LLC
An institutional investment firm that manages a portfolio of public and private equity investments.
CG Oncology, Inc.
A clinical-stage biopharmaceutical company focused on developing antibody-based immunotherapies for solid tumor cancers.
The takeaway
Mangrove Partners' increased stake in CG Oncology suggests the investment firm sees significant potential in the biotech company's pipeline of novel cancer treatments. This vote of confidence from a major institutional investor could signal positive momentum for CG Oncology as it continues advancing its clinical programs.
